371 related articles for article (PubMed ID: 24347294)
1. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
[TBL] [Abstract][Full Text] [Related]
2. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
[TBL] [Abstract][Full Text] [Related]
3. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
4. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
[TBL] [Abstract][Full Text] [Related]
5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
6. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
[TBL] [Abstract][Full Text] [Related]
7. Ferritin and LIC: predicting liver injury in children with sickle cell.
Smith E; Lebensburger J; Hilliard L; Kelly D; Fineberg N; Bai S; Howard T
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):387-90. PubMed ID: 24553473
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
9. Post-transfusional iron overload in the haemoglobinopathies.
Thuret I
C R Biol; 2013 Mar; 336(3):164-72. PubMed ID: 23643400
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease.
Tsitsikas DA; Nzouakou R; Ameen V; Sirigireddy B; Amos RJ
Eur J Haematol; 2014 Feb; 92(2):164-7. PubMed ID: 24175986
[TBL] [Abstract][Full Text] [Related]
11. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
[TBL] [Abstract][Full Text] [Related]
12. Nontransferrin-bound iron in transfused patients with sickle cell disease.
Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT
Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180
[TBL] [Abstract][Full Text] [Related]
13. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
[TBL] [Abstract][Full Text] [Related]
14. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
15. Measurement and mapping of liver iron concentrations using magnetic resonance imaging.
St Pierre TG; Clark PR; Chua-Anusorn W
Ann N Y Acad Sci; 2005; 1054():379-85. PubMed ID: 16339686
[TBL] [Abstract][Full Text] [Related]
16. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
17. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
[TBL] [Abstract][Full Text] [Related]
18. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels.
Karam LB; Disco D; Jackson SM; Lewin D; McKie V; Baker RD; Baker SS; Laver JH; Nietert PJ; Abboud MR
Pediatr Blood Cancer; 2008 Jan; 50(1):62-5. PubMed ID: 17457853
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
